Radiation recall syndrome in a patient with breast cancer,after introduction of everolimus |
| |
| Affiliation: | 1. Radiotherapy department, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, CS 30519, 54500 Vandœuvre-lès-Nancy, France;2. Radiotherapy department, centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France;1. Department of Radiation Oncology, Complejo Hospitalario Universitario de Albacete (CHUA), C/Hnos Falcó 37, 02006 Albacete, Spain;2. Department of Radiology, Complejo Hospitalario Universitario de Albacete (CHUA), C/Hnos Falcó 37, 02006 Albacete, Spain;3. Department of Radiation Oncology, Hospital Son Espases, Carr. de Valldemossa, 79, 07120 Palma, Spain;4. Department of Radiation Oncology, Hospital Clinic, Villarroel, 170, 08036 Barcelona, Spain;5. Charité - Universitätsmedizin Berlin, Berlin, Germany;6. Department of Radiation Oncology, Hospital Universitari Sant Joan, Av. del Dr. Josep Laporte, 2, 43204 Reus, Spain;1. Départment de radiothérapie, institut Claudius-Regaud, institut universitaire du cancer de Toulouse – Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France;2. Institut de recherche biomédicale des armées, BP73, 91223 Brétigny-sur-Orge cedex, France;3. Département de radiothérapie, institut de cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France;4. Laboratoire de radiobiologie cellulaire et moléculaire, UMR 5822, institut de physique nucléaire de Lyon (IPNL), 69622 Villeurbanne, France;5. UMR 5822, CNRS, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France;6. UMR 5822, université Lyon 1, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France;7. UMR 5822, université de Lyon, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France;8. Service de santé des armées, école du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France;9. Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vailant, 94805 Villejuif, France;1. Medical oncology department, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France;2. Clinical hematology department, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France;3. Radiation oncology department, institut Curie, 26, rue d’Ulm, 75005 Paris, France;4. Nuclear medicine department, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France |
| |
| Abstract: | The addition of everolimus to exemestane is recommended in patients with HR+ advanced breast cancer with disease recurrence or progression following prior non-steroidal aromatase inhibitors. We report a case of radiation recall syndrome in a breast cancer patient, after introduction of everolimus. A woman with a right breast cancer underwent a mastectomy, then adjuvant chemotherapy, radiation therapy and hormonotherapy. In a phase III trial (UNIRAD protocol), she received everolimus 5 months after radiation therapy. Seven days after introduction, she was suffering from a radiation recall syndrome with exacerbation skin reactions. The exact pathophysiological mechanism of radiation recall syndrome is unknown. The combination of radiation therapy and mTor inhibitor, even sequentially, should be done with caution as several cases have already been reported. |
| |
| Keywords: | Radiation recall syndrome Everolimus Radiation therapy Évérolimus Radiothérapie |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
